A 2-stage Phase 1 Study of Safety, Tolerability, PK, and PD of IW-1973 Tablet in Healthy Volunteers in an Open-label, Single-dose Stage, and a Randomized, Double Blind, Placebo-controlled, Multiple-ascending-dose Stage
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Praliciguat (Primary)
- Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Ironwood Pharmaceuticals
- 17 Sep 2017 Results presented at the Council on Hypertension Scientific Session 2017
- 25 Aug 2016 Status changed from active, no longer recruiting to completed.
- 31 May 2016 Planned End Date changed from 1 Sep 2016 to 1 Jun 2016.